Tenapanor - Ardelyx

Drug Profile

Tenapanor - Ardelyx

Alternative Names: AZD-1722; AZD1722-hydrochloride; RDX-5791; Tenapanor hydrochloride

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardelyx
  • Developer Ardelyx; AstraZeneca
  • Class Benzylisoquinolines; Gastrokinetics; Irritable bowel syndrome therapies; Small molecules; Sulfonamides
  • Mechanism of Action Fibroblast growth factor 23 expression inhibitors; Sodium-hydrogen exchanger 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperphosphataemia; Irritable bowel syndrome
  • Phase II Renal failure
  • No development reported Heart failure

Most Recent Events

  • 19 Mar 2018 Knight Therapeutics receives marketing license for Tenapanor in Canada
  • 14 Mar 2018 Ardelyx has patent protection for tenapanor in Australia, South Korea, China, the European Union, Mexico, and Israel
  • 14 Mar 2018 Ardelyx announces intention to submit NDA to US FDA for Hyperphosphataemia in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top